Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Year: 2022
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
Authors: Qing Zhou, Ming Chen, Ou Jiang, Yi Pan, Desheng Hu, Qin Lin, Gang Wu, Jiuwei Cui, Jianhua Chang, Yufeng Cheng, Cheng Huang, Anwen Liu, Nong Yang, Youling Gong, Chuan Zhu, Zhiyong Ma, Jian Fang, Gongyan Chen, Jun Zhao, Anhui Shi, Yingcheng Lin, Guanghui Li, Yunpeng Liu, Dong Wang, Rong Wu, Xinhua Xu, Jianhua Shi, Zhihua Liu, Na Cui, Jingru Wang, Qiang Wang, Ran Zhang, Jason Yang, Yi-Long Wu
Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, University of Chinese Academy of Sciences, Hubei Cancer Hospital, First Affiliated Hospital of Xiamen University, Wuhan Union Hospital, Huazhong University of Science and Technology, First Hospital of Jilin University, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University, Fudan University Shanghai Cancer Center, Qilu Hospital of Shandong University, Fujian Medical University, Fujian Provincial Cancer Hospital, Second Affiliated Hospital of Nanchang University, Hunan Cancer Hospital, West China Hospital of Sichuan University, Chongqing University, Zhengzhou University, Henan Cancer Hospital, Peking University Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, Cancer Hospital of Shantou University Medical College, Army Medical University, Xinqiao Hospital, First Hospital of China Medical University, China Medical University, China Three Gorges University, Yichang Central People's Hospital, Jiangxi Provincial Cancer Hospital, CStone Pharmaceuticals (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Awards: G6935787720, G932695586
OpenAlex ID: W4206406697